Research progress on selective immunoproteasome inhibitors
- Author:
Limin KONG
1
;
Jingyi LU
2
;
Huajian ZHU
2
;
Jiankang ZHANG
2
Author Information
1. Department of Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
2. School of Medicine, Zhejiang University City College, Hangzhou 310015, China
- From:
Journal of Zhejiang University. Medical sciences
2019;48(6):688-694
- CountryChina
- Language:Chinese
-
Abstract:
Immunoproteasome is associated with various diseases such as hematologic malignancies, inflammatory, autoimmune and central nervous system diseases, and over expression of immunoproteasome is observed in all of these diseases. Immunoproteasome inhibitors can reduce the expression of immunoproteasome by inhibiting the production of related cell-inducing factors and the activity of T lymphocyte for treating related diseases. In order to achieve good efficacy and reduce the toxic effects, key for development of selective immunoproteasome inhibitors is the high selectivity and potent activity of the three active subunits of the proteasome. This review summarizes the structure and functions of immunoproteasome and the associated diseases. Besides, structure, activity and status of selective immunoproteasome inhibitors are also been highlighted.
